 DesignMethods: Patients with uncontrolled partial or generalized epilepsy characterized by at least 4 seizuresmonth will be randomized to placebo vs. PUFA in a double-blind fashion. Subjects will remain on their current drugs while a 4-week baseline seizure count occurs. Dosage will then be titrated over 1 week to 1.1 grams twice daily, and will be followed by a 15-week treatment phase with monthly visits, seizure counts, pill counts, AED levels, adverse event reporting, and neurological examinations. Quality of life will be measured before and after the study using the SF-36 and the QOLIE Quality of Life in Epilepsy -31. If subjects wish to continue treatment, they will be given the opportunity at the end of the 20-week period, and those randomized to placebo will have the opportunity to begin treatment with PUFA. 